Dow Jones Newswires reporter Peter Loftus has details of Pfizer's decision to aggressively market branded cholesterol-lowering drug Lipitor after the patent expires at the end of November.

Pfizer Inc (NYSE:PFE) has agreed to pay $93 million to settle an antitrust lawsuit related to its cholesterol drug Lipitor.

The lawsuits consolidated in New Jersey federal court allege that Pfizer sought to maintain its Lipitor monopoly through an illegal scheme with India’s Ranbaxy, acquired by Sun Pharma in 2014.

Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower cholesterol, resulting in buyers paying ...

Pfizer lost its patent on the cholesterol-lowering drug Lipitor on November 30 -- which spells big savings for many of the 8.7 million Americans who take the medication. The patent’s expiration ...